These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 20199974)

  • 21. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor as a target to improve treatment of lung cancer.
    Andratschke NH; Dittmann KH; Mason KA; Fan Z; Liao Z; Komaki R; Ang KK; Milas L
    Clin Lung Cancer; 2004 May; 5(6):340-52. PubMed ID: 15217533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.
    Ochs JS
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):941-9. PubMed ID: 14967454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cetuximab in advanced non-small cell lung cancer.
    Govindan R
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4241s-4244s. PubMed ID: 15217966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
    Marco S; Tomasini P; Greillier L; Barlesi F
    Rev Mal Respir; 2011 Dec; 28(10):1216-29. PubMed ID: 22152931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer.
    Nanda A; Dias-Santagata DC; Stubbs H; O'Hara CJ; Zaner KS; Lynch TJ; Willers H
    Clin Lung Cancer; 2008 Sep; 9(5):285-7. PubMed ID: 18824451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?
    Raben D; Ryan A
    Clin Lung Cancer; 2005 Nov; 7(3):175-9. PubMed ID: 16354311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapy in non-small-cell lung cancer.
    Herbst RS
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 9):19-24. PubMed ID: 12375797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells.
    Iwasa T; Okamoto I; Suzuki M; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
    Clin Cancer Res; 2009 Aug; 15(16):5117-25. PubMed ID: 19671857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The place of targeted therapies in the management of non-small cell bronchial carcinoma. Target therapies in lung cancer management.
    Scagliotti GV; Selvaggi G
    Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S137-16S147. PubMed ID: 17268351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Targeted therapies and radiation therapy in non-small cell lung cancer].
    Rivera S; Quéro L; Wong Hee Kam S; Maylin C; Deutsch E; Hennequin C
    Cancer Radiother; 2011 Oct; 15(6-7):527-35. PubMed ID: 21885318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic integration of new molecule-targeted therapies with radiotherapy in lung cancer.
    Provencio M; Sánchez A
    Transl Lung Cancer Res; 2014 Apr; 3(2):89-94. PubMed ID: 25806286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
    Huber RM; Reck M; Thomas M
    Eur Respir J; 2013 Oct; 42(4):1119-33. PubMed ID: 23429914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicity of targeted therapy in non-small-cell lung cancer management.
    Ricciardi S; Tomao S; de Marinis F
    Clin Lung Cancer; 2009 Jan; 10(1):28-35. PubMed ID: 19289369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stepwise progress in epidermal growth factor receptor/radiation studies for head and neck cancer.
    Harari PM
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S25-7. PubMed ID: 17848286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.
    Santarpia M; Altavilla G; Pitini V; Rosell R
    Future Oncol; 2015; 11(8):1259-74. PubMed ID: 25832881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracytoplasmic epidermal growth factor receptor shows poor response to the cetuximab antitumor effect in irradiated non-small cell lung cancer cell lines.
    Ryu SH; Lee SW; Yang YJ; Song SY; Kim JH; Choi EK; Ahn SD
    Lung Cancer; 2012 Sep; 77(3):482-7. PubMed ID: 22704525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From radiotherapy to Targeted therapy: 20 years in the management of non-small-cell lung cancer.
    Weiss GJ; Bunn PA; Camidge DR
    Oncology (Williston Park); 2006 Nov; 20(12):1515-24; discussion 1524-5, 1530, 1535. PubMed ID: 17153906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular determinants of radiation response in non-small cell lung cancer.
    Yom SS; Diehn M; Raben D
    Semin Radiat Oncol; 2015 Apr; 25(2):67-77. PubMed ID: 25771410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.